Market Overview:
The global monoclonal antibodies market size reached USD 221.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 392.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032. The rising prevalence of chronic disorders such as cancer, autoimmune disorders, and infectious diseases, innovations like bispecific antibodies and antibody-drug conjugates (ADCs), increasing geriatric population, and the expansion in oncology and immunotherapy are propelling the market growth.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
USD 221.7 Billion |
Market Forecast in 2032
|
USD 392.6 Billion |
Market Growth Rate 2024-2032 |
6.4% |
Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targetting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells.
Monoclonal Antibodies Market Trends:
Rising Prevalence of Chronic Diseases
The market is expanding as a result of an increase in the prevalence of chronic illnesses such diabetes, cancer, autoimmune disorders, and infectious diseases. As an alternative to chemotherapy, these antibodies help target medicines that can attach to sick cells selectively and allow for more targeted treatment with fewer adverse effects. They help the immune system eliminate malignant cells by targeting particular proteins on the surface of cancer cells that prevent tumor growth. In addition, as chronic conditions continue to rise because of lifestyle factors, aging populations, and environmental factors, monoclonal antibodies market scope is expected to grow significantly. According to the International Diabetes Federation (IDF), 643 million people worldwide are expected to have diabetes by 2030.
Advancements in Biotechnology and Genetic Engineering
Innovations such as phage display, transgenic animal models, and recombinant deoxyribonucleic acid (DNA) technology allow the production of antibodies having improved specificity, decreased immunogenicity, and extended half-lives. The introduction of new formats like antibody-drug conjugates (ADCs), can carry lethal medicines directly to target cells, and bispecific antibodies, can target two different antigens at once. As a result, these developments make therapies more effective while reducing adverse effects, making them very appealing for complicated illnesses like cancer and autoimmune disorders.
Growing Geriatric Population
The increasing geriatric population is propelling the monoclonal antibodies market growth. Older individuals are at a higher risk of chronic and degenerative illnesses, requiring more advanced medical care. These antibodies can target specific disease markers, which makes them suitable for treating older. They can also minimize negative side effects when compared to traditional treatments. Furthermore, with the increase in life expectancy, the healthcare system is encountering a growing prevalence of age-related illnesses, leading to a higher need for efficient biologic therapies such as monoclonal antibodies. The World Health Organization (WHO) has projected that 426 million people will be 80 years of age or older in 2050.
Monoclonal Antibodies Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global monoclonal antibodies market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on production method, source, indication and end use.
Breakup by Production Method:
Breakup by Source:
- Murine
- Chimeric
- Humanized
- Human
Breakup by Indication:
- Cancer
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Others
Breakup by End Use:
- Hospitals
- Research Institutes
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global monoclonal antibodies market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
- AbbVie Inc.
- Amgen Inc.
- Biogen Inc.
- F. Hoffmann-La Roche AG
- GSK plc
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi S.A.
- Thermo Fisher Scientific Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Monoclonal Antibodies Market News:
- 25 July 2024: Harbour BioMed unveiled that it will release the latest clinical data on its first-in-class fully human anti-B7H7/HHLA2 monoclonal antibody, HBM1020, for advanced solid tumors at the ESMO Congress 2024.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
Billion USD |
Segment Coverage |
Production Method, Source, Indication, End Use, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc. |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |